BioMérieux: growth of over 6% in Q1
"The 14% growth in sales of Biofire panels and the promising launch of the Spotfire solution illustrate the ever-growing interest in the syndromic approach", stresses CEO Pierre Boulud, also pointing to the performance in microbiology (+9%).
The in vitro diagnostics specialist confirms its targets for 2024 of organic sales growth of between +6 and +8%, and growth in profit from recurring operations of at least +10% at constant exchange rates.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction